乳腺癌药物耐药性中的circRNAs
Sema Misir1, Serap Ozer Yaman2, Nina Petrović3,4
1Department of Biochemistry, Faculty of Pharmacy, Sivas Cumhuriyet University, Sivas, 58010, Turkey.
Oncology research
|June 12, 2023
概括
循环RNAs (circRNAs) 在乳腺癌 (BC) 耐药性中发挥关键作用,通过影响药物流失和亡等机制. 了解circRNAs为克服BC中的化学抵抗提供了新的治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 乳腺癌 (BC) 是女性癌症死亡的主要原因,治疗疗效通常受药物耐药性限制.
- 在BC的化疗耐药性是一个重大的临床挑战,需要新的治疗策略.
- 循环RNAs (circRNAs) 是一种非编码RNAs类,它们在癌症进展和药物耐药性方面的作用越来越被认可.
研究的目的:
- 为了审查circRNAs的生物特性.
- 阐明circRNAs在BC中诱导对常规抗癌药物耐药性的机制.
- 总结circRNAs在BC化学抵抗中的潜在作用,包括药物排泄,亡功能障碍,自和DNA损伤修复.
主要方法:
- 对研究研究乳腺癌中circRNAs的文献综述.
- 对circRNA参与已建立的耐药性途径的分析.
- 对BC化学抵抗中的circRNA功能的当前证据的综合.
主要成果:
- 循环RNAs通过促进通过ATP结合盒 (ABC) 载体促进药物排放等机制,促进BC药物耐药性.
- 一些circRNAs通过抑制BC细胞的亡来诱导对他莫西芬的耐药性.
- 其他circRNAs通过调解BC细胞中多克索鲁比诱导的自来促进化学抵抗.
结论:
- 循环RNA与BC药物耐药性的多种机制有关,包括改变的亡和自.
- 循环RNAs代表预测BC化学抵抗的潜在生物标志物.
- 向circRNAs可能为克服耐药性和推进个性化BC治疗提供新的治疗策略.
相关概念视频
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Cancer-Critical Genes I: Proto-oncogenes
9.0K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.0K
Transducer Mechanism: Nuclear Receptors
1.4K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.4K


